Review
Oncology
Ying Gong, Roel G. J. Klein Wolterink, Jianxiang Wang, Gerard M. J. Bos, Wilfred T. V. Germeraad
Summary: NK cells, especially CAR-NK cells, play a crucial role in cancer treatment. Advances in CAR-NK technology show promising potential in efficiently targeting cancer cells with reduced side effects. These developments contribute to improving cancer treatment strategies.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2021)
Article
Oncology
P. Connor Johnson, Caron Jacobson, Alisha Yi, Mahmoud R. Gaballa, Nora Horick, Dustin J. Rabideau, Kevin Lindell, Gabriel D. DePinho, Areej R. El-Jawahri, Matthew J. Frigault
Summary: A retrospective analysis of 235 patients receiving CAR T-cell therapy found that bridging therapy use was not associated with differences in overall response, complete response rate, or progression-free survival, but was associated with worse overall survival. Additional poor prognostic factors may contribute to this association, highlighting the need for innovative bridging therapy regimens for these patients.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Review
Biochemistry & Molecular Biology
Rodrigo C. C. De Marco, Hector J. J. Monzo, Paivi M. Ojala
Summary: With the continuous advancements in immunotherapy and precision medicine, adoptive cell therapy (ACT) has emerged as a new treatment approach in oncology. Chimeric antigen receptor (CAR) T cells, genetically modified lymphocytes, have shown promising results in targeting and killing cancer cells. Commercialization of CAR T cell therapy has paved the way for future bright developments.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Congcong Zhang, Jasmin Roeder, Anne Scherer, Malena Bodden, Jordi Pfeifer Serrahima, Anita Bhatti, Anja Waldmann, Nina Mueller, Pranav Oberoi, Winfried S. Wels
Summary: The study developed a bispecific antibody NKAB-ErbB2 that redirects NKG2D-expressing effector cells to ErbB2-positive tumor cells, synergizing with NKG2D-CAR cells and natural NK cell-mediated cytotoxicity. In mouse model, NKAR-NK-92 cells combined with NKAB-ErbB2 effectively suppressed tumor outgrowth and induced antitumor immunity and cures in most animals.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Biochemistry & Molecular Biology
Ruediger Klapdor, Shuo Wang, Michael A. Morgan, Katharina Zimmermann, Jens Hachenberg, Hildegard Buening, Thilo Doerk, Peter Hillemanns, Axel Schambach
Summary: Ovarian cancer stem cells with chemoresistance contribute to tumor recurrence, leading to poor survival rates. Targeting CD44 using CAR immunotherapy demonstrates potent cytotoxic activity against CD44-positive ovarian cancer cells. Furthermore, combined treatment of CD44-targeted therapy and cisplatin shows higher anti-tumor activity compared to sequential treatment.
Review
Immunology
Peng Zhang, Yang Zhang, Nan Ji
Summary: Glioblastoma (GBM) is a deadly brain cancer with limited efficacy of standard treatments, necessitating the development of new therapies. Chimeric antigen receptor T (CAR-T) cell immunotherapy has shown success in hematological malignancies, but has not yet yielded promising results in GBM. CAR-T cell therapy for GBM faces challenges including tumor heterogeneity, immunosuppressive microenvironment, and cell persistence.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Simone Thomas, Hinrich Abken
Summary: Chimeric antigen receptors (CARs) in the second generation format provide two signals for T cell activation. However, CAR T cell persistence is limited and can be improved by supplementing cytokines as the third signal. Recent progress in understanding receptor signaling allows for the engineering of cytokines to selectively stimulate CAR T cells. We discuss strategies for engineering cytokine help intensified CAR (CHIC) T cells for adoptive cell therapy.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Vita Golubovskaya, Hua Zhou, Feng Li, Robert Berahovich, Jinying Sun, Michael Valentine, Shirley Xu, Hizkia Harto, John Sienkiewicz, Yanwei Huang, Lijun Wu
Summary: This study focused on developing novel CS1 CAR-T cells and bispecific CS1-BCMA CAR-T cells for targeting multiple myeloma. The experimental results demonstrated that these cells effectively killed multiple myeloma cells, showing promise for future clinical trials.
Review
Oncology
Giuseppe Schepisi, Caterina Gianni, Michela Palleschi, Sara Bleve, Chiara Casadei, Cristian Lolli, Laura Ridolfi, Giovanni Martinelli, Ugo De Giorgi
Summary: To date, various therapeutic strategies, including immunotherapies, have been successful in prolonging the survival of breast cancer patients. Our article focuses on the application of chimeric antigen receptor-based immunotherapy in breast cancer.
Article
Immunology
Rui Zheng, Yuankun Chen, Yiting Zhang, Sixin Liang, Xiaojuan Zhao, Yiyi Wang, Pengju Wang, Ruotong Meng, Angang Yang, Bo Yan
Summary: Our study explores the effect of low-affinity CARs using humanized scFvs on the function of CAR-T cells. We find that moderately reducing the affinity of CARs can maintain anti-tumor efficacy and improve the safety of CAR therapy both in vitro and in vivo. In addition, T cells expressing the VL domain only antibody show long-lasting tumor elimination capability and lower cytokine levels.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Oncology
Elien De Bousser, Nico Callewaert, Nele Festjens
Summary: T cell-engaging immunotherapy aims to activate cytotoxic T cells to destroy cancer cells, while CAR T cell therapy redirects immune cells to recognize tumor antigens. Despite success, challenges such as toxicities and limited efficacy need to be addressed for the broad use of CAR T cell therapy. Research is ongoing to develop more powerful CAR T cells.
Article
Biotechnology & Applied Microbiology
Jingting Min, Chirong Long, Lu Zhang, Jiakang Duan, Honglian Fan, Fei Chu, Zhenghong Li
Summary: Non-small cell lung cancer (NSCLC) is a prevalent and fatal malignancy, and CAR-T cell therapy targeting c-Met shows potential as a therapeutic strategy. In vitro and in vivo experiments demonstrated that c-Met CAR-T cells exhibit enhanced cytotoxicity against NSCLC cells.
Review
Neurosciences
Lisa Feldman, Christine Brown, Behnam Badie
Summary: Glioblastoma is the most common and aggressive primary brain tumor in adults, and current mainstay treatments are ineffective, leading to the development of immunotherapy strategies. CAR T cell therapy uses genetically modified T cells to target tumor-associated antigens and has the potential to destroy tumor cells.
NEUROMOLECULAR MEDICINE
(2022)
Article
Immunology
Karin Teppert, Nora Winter, Vera Herbel, Caroline Brandes, Simon Lennartz, Fabian Engert, Andrew Kaiser, Thomas Schaser, Dominik Lock
Summary: The prognosis for patients with metastatic melanoma is poor and treatment options are limited. However, genetically-engineered T cell therapy targeting CSPG4 shows promise as a potential treatment. Combining a chimeric co-stimulatory receptor (CCR) and a CSPG4-directed chimeric antigen receptor (CAR) enhances the anti-tumor response and provides a new approach for treating metastatic melanoma.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Oncology
Ke-Tao Jin, Bo Chen, Yu-Yao Liu, H. uan-Rong Lan, Jie-Ping Yan
Summary: Colorectal cancer is the third most common cancer globally with immunotherapy, including monoclonal antibodies and CAR-T cells, emerging as novel therapeutic approaches. Both monoclonal antibodies and CAR-T cells have beneficial anti-tumor effects on CRC by eliciting immune responses against tumor cells.
CANCER CELL INTERNATIONAL
(2021)